Key Cell Types and Activated Pathways in Psoriatic Arthritis Role of IL17 Signaling Pharmacologic Agents Indicated for the Treatment of PsA FUTURE 1 Efficacy and Safety of Secukinumab FUTURE 2 ID: 775426
Download Presentation The PPT/PDF document " Psoriatic Arthritis Introduction to PsA" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Psoriatic Arthritis
Slide2Introduction to PsA
Slide3Key Cell Types and Activated Pathways in Psoriatic Arthritis
Slide4Role of IL-17 Signaling
Slide5Pharmacologic Agents Indicated for the Treatment of PsA
Slide6FUTURE 1Efficacy and Safety of Secukinumab
Slide7FUTURE 2Efficacy and Safety of SC Secukinumab
Slide8FUTURE 2: Efficacy of Secukinumab in Anti-TNF-Naive and Anti-TNF-IR Patients
Slide9FUTURE 5Improvement in Radiographic Progression
Slide10Summary of Pooled Safety Across FUTURE 1 and FUTURE 2 Studies
Slide11Ixekizumab for the Treatment of PsA SPIRIT-P1 Results
Slide12SPIRIT-P2Ixekizumab for the Treatment of PsA in TNF-IR Patients
Slide13Frequency of AEs Across SPIRIT-P1 and SPIRIT-P2 Studies
Slide14SPIRIT-H2H: Study Comparing Safety and Efficacy of Ixekizumab and Adalimumab in PsA
Slide15SPIRIT-H2H Results Primary and Secondary Outcomes at Week 24
Slide16Safety and Efficacy of Bimekizumab in Patients With PsA
Slide17GRAPPA Treatment Scheme
Slide18Enthesitis in PsA
Slide19IL-17 Inhibitors in the Treatment of Enthesitis
Slide20Dactylitis in PsA
Slide21IL-17 Inhibitors in the Treatment of Dactylitis
Slide22MAXIMISE TrialManaging Axial Manifestations in Patients With PsA
Slide23Concluding Remarks
Slide24Slide25Abbreviations
Slide26Abbreviations (cont)
Slide27Abbreviations (cont)